Literature DB >> 10408566

Lethal capillary leak syndrome after a single administration of interferon beta-1b.

S Schmidt1, H J Hertfelder, T von Spiegel, R Hering, M Harzheim, H Lassmann, M Deckert-Schlüter, U Schlegel.   

Abstract

Interferon beta-1b (IFNbeta-1b) is a potent immunomodulatory drug in the treatment of MS. We report a lethal capillary leak syndrome after the administration of IFNbeta-1b in a patient with disseminated white matter disease, monoclonal gammopathy, and acquired C1 inhibitor (C1-INH) deficiency. IFNbeta-1b may cause a transient release of proinflammatory cytokines finally resulting in an uninhibited activation of the complement cascade in patients with C1-INH deficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408566     DOI: 10.1212/wnl.53.1.220

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

Review 1.  Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

Authors:  R Hohlfeld
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 2.  C1 inhibitor: molecular and clinical aspects.

Authors:  Marco Cicardi; Lorenza Zingale; Andrea Zanichelli; Emanuela Pappalardo; Benedetta Cicardi
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

3.  Possible involvement of interferon beta in post-operative vasculitis restricted to the tumour bed: a case report.

Authors:  Tatsuya Abe; Kenji Sugita; Masaki Morishige; Kouhei Ohnishi; Keisuke Ishii; Tohru Kamida; Takamitsu Hikawa; Minoru Fujiki; Hidenori Kobayashi; Kenji Kashima; Shigeo Yokoyama
Journal:  Neurosurg Rev       Date:  2008-07-11       Impact factor: 3.042

Review 4.  Requirement for safety monitoring for approved multiple sclerosis therapies: an overview.

Authors:  P S Rommer; U K Zettl; B Kieseier; H-P Hartung; T Menge; E Frohman; B M Greenberg; B Hemmer; O Stüve
Journal:  Clin Exp Immunol       Date:  2014-03       Impact factor: 4.330

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.